Cornelis Melief

Last updated

Cornelis Joseph Maria Melief (born 20 January 1943) is a immunologuist [1] specialising in cancer immunology and immunotherapy, with a focus on therapeutic cancer vaccines. He is emeritus Professor, former head of the Department of Immunohematology and Blood Transfusion at the Leiden University Medical Center, [1] and Chief Scientific Officer at ISA Therapeutics in Netherlands. [2] He is known for his work in the field of cancer immunology, [1] devising new cancer therapies based on the activation of the patient's own immune system.

Contents

Early life and education

He grew up in the South of the Netherlands, in the town of Zevenbergschen Hoek  [ nl ] and from 11 years of age onwards in Amsterdam. He received his PhD Doctorate in Medicine in 1967 from the University of Amsterdam, followed by a Medical Doctor degree in 1970 from the same university. In 1973 and 1974 he was a postdoctoral fellow at the New England Medical Center and Dana-Farber Cancer Institute in Boston.

From 1970 to 1972, Melief served as an MD Lieutenant as part of compulsory Army conscription in the Netherlands.

Career

In 1975, he joined the Netherlands Red Cross Blood Transfusion Service, as Head of Department of cell-mediated immunology. From 1975 to 1985 he became a scientific staff member of the CLB Amsterdam. In 1976, Melief was made head of the new Department of Experimental Tumour Immunology which in 1982 was renamed the Department of Cellular Immunology.

From 1985 to 1991, he worked as the Head of the Division of Immunology at the Netherlands Cancer Institute [3] in Amsterdam. In 1991, he became head of the Department of Immunohematology and blood transfusion at Leiden University Medical Center. In 2004 he co-founded and became Chief Scientific Officer at the Biotech company Immune System Activation (ISA) Pharmaceuticals [2]

Since 2012, Melief has been the CSO of ISA Pharmaceuticals and emeritus Professor at Leiden University Medical Center.

Major accomplishments

He is author of more than 550 peer-reviewed publications, cited over 71,000 times [4] and inventor on more than 30 patents and patent applications.

Major patents include:

Major publications include:

Memberships

Awards and honours

Related Research Articles

Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

The Society for Immunotherapy of Cancer (SITC), previously known as the International Society for Biological Therapy of Cancer (iSBTc), is a professional society of scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving outcomes in patients with cancer by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 2,400 members, representing 22 medical specialties from 42 countries around the world, who are engaged in the research and treatment of cancer.

<span class="mw-page-title-main">Georges Mathé</span> French oncologist and immunologist (1922–2010)

Georges Mathé was a French oncologist and immunologist. In November 1958, he performed the first successful allogeneic bone marrow transplant ever performed on unrelated human beings.

<span class="mw-page-title-main">Compugen Ltd.</span> Israeli biotechnology company

CompugenLtd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Nektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.

<span class="mw-page-title-main">Immune checkpoint</span> Regulators of the immune system

Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately. However, some cancers can protect themselves from attack by stimulating immune checkpoint targets.

<span class="mw-page-title-main">Holger Lode</span> German specialist for pediatrics (born 1967)

Holger Lode is a German specialist for pediatrics. He is Professor and Chair of the Department of General Pediatrics and Pediatric Hematology and Oncology at the University Medicine Greifswald. He is also the director of the Center of Pediatrics and Adolescent Medicine in Greifswald. Lode is well known for his clinical and scientific work on immunotherapy of neuroblastoma.

<span class="mw-page-title-main">Hans-Georg Rammensee</span>

Hans-Georg Rammensee is a German immunologist and cancer researcher. He has been Chair Professor and Head of the Department of Immunology at the University of Tübingen since 1996. Rammensee has contributed essentially to the research fields of MHC biology and tumor immunology and to the development of cancer immunotherapies.

Yu Baofa is a Chinese oncologist and researcher in intratumoral cancer therapy and drug development. He is the Founder, CEO and Chairman of Baofa Cancer Hospital Network China in Jinan, Beijing and Dongping. He also developed Ultra Minimum Incision Personalized Intra-Tumoral Chemo-Immuno (UMIPIC) Therapy.

Miram Merad is a French-Algerian professor in Cancer immunology and the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology and a member of the United States National Academy of Sciences and the National Academy of Medicine.

APC Activators are a type of immunotherapy which leverages antigen-presenting cells (APCs) to drive an adaptive immune response. APC Activators are agonists to APC surface-expressed ligands that, when bound, induce the maturation and activation of APCs. Professional antigen-presenting cells – including dendritic cells, macrophages, and B cells – serve an indispensable role in the adaptive immune response through their unique ability to phagocytose, digest, and present exogenous (circulating) antigens to T cells, facilitating antigen-specific immune responses.

Laurence Zitvogel is a French physician-scientist specializing in oncology and immunology; her primary research experience is in exosomes and the biological impact of structural abnormalities on malignant neoplasms and anti-tumor therapy.

<span class="mw-page-title-main">Uğur Şahin</span> German oncologist and immunologist (born 1965)

Uğur Şahin is a German oncologist and immunologist. He is the founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.

Adekunle O. Odunsi is an American gynecologic oncologist. In 2021, Odunsi became the director of the University of Chicago Comprehensive Cancer Center.

<span class="mw-page-title-main">George Coukos</span> Tumor immunologist

George Coukos is a physician-scientist in tumor immunology, professor and director of the Ludwig Cancer Research Lausanne Branch and director of the Department of oncology UNIL-CHUV of the University of Lausanne and the Lausanne University Hospital in Lausanne, Switzerland. He is known for his work on the mechanisms by which tumors suppress anti-cancer immune responses, and the role of the tumor vasculature in that suppression. In addition to his work in ovarian cancer, the combinatorial immune therapies proposed by Professor Coukos have been successfully tested and approved for lung, liver and kidney cancers.

Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.

<span class="mw-page-title-main">Marcin Kortylewski</span> Polish American cancer researcher and immunologist

Marcin Kortylewski is a Polish American cancer researcher and immunologist. He is currently professor of immuno-oncology at the Beckman Research Institute of the City of Hope National Medical Center in Duarte, California. His research has shown that the STAT3 protein plays a role in protecting cancers from immune responses and contributes to resistance to therapies. Later he developed a two-pronged strategy for cancer immunotherapy using simultaneous STAT3 inhibition and TLR9 immune stimulation. Kortylewski invented platform strategy for delivery of oligonucleotides, such as siRNA, miRNA, decoy DNA, antisense molecules and others to selected immune cells.

References

  1. 1 2 3 "Cornelis J.M. Melief, M.D., Ph.D." Cancer Research Institute. Retrieved 2022-06-13.
  2. 1 2 "Kees Melief". ISA Therapeutics BV. Retrieved 2022-06-13.
  3. ↑ "NKI | Netherlands Cancer Institute". www.nki.nl. Retrieved 2022-06-13.
  4. ↑ "Profiles". scholar.google.co.uk. Retrieved 2022-06-13.
  5. ↑ "US Patent Application for Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40 Patent Application (Application #20050255106 issued November 17, 2005) - Justia Patents Search". patents.justia.com. Retrieved 2022-06-13.
  6. ↑ "US Patent Application for Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses Patent Application (Application #20070292449 issued December 20, 2007) - Justia Patents Search". patents.justia.com. Retrieved 2022-06-13.
  7. ↑ Schoenberger, Stephen P.; Toes, Rene E. M.; van der Voort, Ellen I. H.; Offringa, Rienk; Melief, Cornelis J. M. (June 1998). "T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions". Nature. 393 (6684): 480–483. Bibcode:1998Natur.393..480S. doi:10.1038/31002. ISSN   1476-4687. PMID   9624005. S2CID   4427174.
  8. ↑ Kenter GG, Welters MJ, Valentjin AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (November 5, 2009). "Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia". New England Journal of Medicine. 361 (19): 1838–47. doi: 10.1056/NEJMoa0810097 . PMID   19890126.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ↑ Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, Reyners AKL, Velu T, Goffin F, Lalisang RI, Loof NM, Boekestijn S, Krebber WJ, Hooftman L, Visscher S, Blumenstein BA, Stead RB, Gerritsen W, van der Berg SH (March 18, 2020). "Strong vaccines responses during chemotherapy are associated with prolonged cancer survival". Sci Transl Med. 12 (535): eaaz8235. doi:10.1126/scitranslmed.aaz8235. hdl: 2268/309154 . PMID   32188726. S2CID   213182500.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ↑ "Cancer Research". American Association for Cancer Research. Retrieved 2022-06-13.
  11. ↑ "Kees Melief" (in Dutch). Royal Netherlands Academy of Arts and Sciences. Retrieved 9 December 2023.
  12. ↑ "ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Honored by the Association for Cancer Immunotherapy (CIMT)". ISA Therapeutics BV. 2017-05-11. Retrieved 2022-06-13.
  13. ↑ Nobel, Akzo (1995). "Akzonobel annual report 1995" (PDF). Akzo Nobel.
  14. ↑ "EFIS – European Federation of Immunological Societies: EFIS-IL Lecture Award". www.efis.org. Retrieved 2022-06-13.
  15. ↑ EFI, EUROPEAN FEDERATION FOR IMMUNOGENETICS (30 September 2021). "The Ceppellini Lecture" (PDF). European Federation for Immunogenetics.
  16. ↑ "2009 Grace and Coley Award Winners Announced". www.newswise.com. Retrieved 2022-06-13.
  17. ↑ "Lifetime Achievement". CIMT. Retrieved 2022-06-13.
  18. ↑ "Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg University Mainz". ISA Therapeutics BV. 2017-10-26. Retrieved 2022-06-13.
  19. ↑ "2018 ESMO Immuno-Oncology Award Goes to Cornelis Melief". www.urotoday.com. Retrieved 2022-06-13.
  20. ↑ "Cornelis Melief Honored With AACR-CRI Award in Cancer Immunology - The ASCO Post". ascopost.com. Retrieved 2022-06-13.
  21. ↑ ISA Pharmaceuticals. "Professor Melief to receive 2022 Pedro J. Romero Service to JITC Award from Society for Immunotherapy of Cancer". Cision PR Newswire (Press release). PR Newswire. Retrieved 2023-06-13.
  22. ↑ "SITC press release". July 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.